Concepedia

Tammie C. Yeh

TC

14

Publications

1.3K

Citations

13

H-Index

1993

Active since

Affiliations

AstraZeneca (United States)(Current)

The University of Texas MD Anderson Cancer Center

Moffitt Cancer Center

University of Washington

Seoul National University Hospital

Tammie C. Yeh is an author at AstraZeneca (United States) specializing in medicine, pharmacotherapy, and radiation oncology.

Top concepts

Publications per year

1993–2024

14

Publications

14

Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor

Tammie C. Yeh, Vivienne Marsh, Bryan A. Bernat et al. · Clinical Cancer Research · 2007 · 575 citations · Full text

AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies

Garrett W. Rhyasen, Maureen M. Hattersley, Yi Yao et al. · Molecular Cancer Therapeutics · 2016 · 147 citations · Full text

, , +17

57O Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): A phase I expansion in TKI-naïve patients (pts) with EGFR mutant NSCLC

Don L. Gibbons, Laura Q.M. Chow, Dongwook Kim et al. · Journal of Thoracic Oncology · 2016 · 109 citations · Full text

, , +5

Characterization and Cloning of a 58/53-kDa Substrate of the Insulin Receptor Tyrosine Kinase

Tammie C. Yeh, Wataru Ogawa, Anne Danielsen et al. · Journal of Biological Chemistry · 1996 · 98 citations · Full text

Ponatinib vs Imatinib in Frontline Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia

Elias Jabbour, Hagop M. Kantarjian, Ibrahim Aldoss et al. · JAMA · 2024 · 90 citations · Full text

Rows per page

1–5 of 14